Treatment of depressive disorders
View Patent ↗The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.
1. A method of treating depression in a subject comprising administering to the subject an effective amount of a composition comprising a bryostatin compound and a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the bryostatin is selected from a group consisting of bryostatin-1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18.
3. The method of claim 2 , wherein the bryostatin is bryostatin-1.
4. The method of claim 1 wherein the bryostatin compound is bryostatin-1.
5. A method of treating depression in a subject comprising administering to the subject an effective amount of a composition comprising bryostatin-1 and a pharmaceutically acceptable carrier.